Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Double-Blind, Placebo-Controlled Multiple-Ascending Dose Study of BMS-820836 in Healthy Japanese Subjects and Japanese Patients With Depression
jRCT2080221590Phase 1
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing BMS-820836 multiple ascending dose with Placebo (2 arms). Primary endpoints: Safety and tolerability of BMS-820836, Pharmacokinetics of BMS-820836 and 1 more.
02
Drugs
liafensine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080221590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221590.